

AroCell appoints professor Ferruccio Bonino to the advisory board

AroCell announces today that professor Ferruccio Bonino joins AroCell's advisory board. Ferruccio Bonino, MD, is full professor of Gastroenterology at the University of Pisa, Department of Clinical and Experimental Medicine, and Senior Research Associate at the Institute of Biostructure and Bioimaging of the National Research Council (IBB-CNR) of Italy.

Professor Bonino is a well-respected scientist and has during his long career contributed greatly to the advancement in science. The study of biomarkers in different diseases has been one of Professor Bonino's great interest over the years. The purpose of AroCell's Advisory Board is to provide expert advice, facilitate important relationships, and guide long-term strategic planning in areas critical to the company's strategy.

"I look forward to collaborating with the multi-competent AroCell team and think that AroCell TK 210 ELISA is an exciting new product with great potential since it provides a specific and sensitive direct measure of circulating TK1 released from disrupted cancer cells during anticancer therapy. It represents a tantalizing new tool to study the relations between TK1 early kinetics, tumor cell loss and response to anticancer therapy. The measure of cancer cells dynamics is a mandatory need in the dashboard of personalized anticancer therapy", said Professor Bonino.

"We warmly welcome Professor Bonino as a member of our Advisory Board," said Anders Hultman, CEO. "Professor Bonino and his extensive experience in the field of gastroenterology and liver will be a valuable contribution and complement to AroCell and the advisory board."

Contacts

Anders Hultman, CEO
Phone: +46(0)18 50 30 20
E-mail: anders.hultman@arocell.com

About AroCell

AroCell AB (publ) is a Swedish company that develops standardized modern blood tests to support the prognosis and follow up of cancer patients. AroCell's new technology is based on patented methods to measure Thymidine Kinase 1 (TK1) protein concentrations in a blood sample. The TK 210 ELISA test provides valuable information mainly about the condition of cancer patients. This may help clinicians to optimize treatment strategies and estimate the risk of recurrence of tumor disease during the monitoring of the disease. AroCell (AROC) is listed at Nasdaq First North Growth Market with Redeye AB as Certified Adviser: Certifiedadviser@redeye.se, +46 (0)8 121 576 90. For more information; www.arocell.com

Press Release
24 June 2021 10:00:00 CEST



Attachments

[AroCell appoints professor Ferruccio Bonino to the advisory board](#)